DK210 + immune checkpoint blockers

DK210 + immune checkpoint blockers is an investigational combination therapy evaluated for advanced solid tumors expressing epidermal growth factor receptor (EGFR). **DK210** is a recombinant immunocytokine that combines wild-type interleukin-2 (IL-2) and a high-affinity variant of interleukin-10 (IL-10), coupled via a single-chain variable fragment (scFv) that binds EGFR. The rationale is to enhance immune activation (driving cytotoxic T and NK cell activity) while limiting systemic toxicity typically associated with IL-2 by leveraging the immunomodulatory effect of IL-10 and targeted delivery to the tumor microenvironment. Immune checkpoint blockers included in the combination are not specified in the available data, but would likely refer to PD-1 or PD-L1 inhibitors. DK210 is being developed as a self-administered subcutaneous injectable, and the combination is under clinical study by Deka Biosciences, targeting multiple solid tumor types including renal cell carcinoma, non-small cell lung cancer, and others[2][3][4][5][7][8][9].

Other names

DK210 (EGFR) in combination with immune checkpoint blockersDK210 (EGFR) + PD-1 blocker